Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SI-B001 + SI-B003 + chemotherapy
- Development stage
- Unknown
- Lead developer
- SystImmune
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
SI-B001 + SI-B003 + chemotherapy is a combination regimen under clinical investigation for the treatment of recurrent, locally advanced, or metastatic head and neck squamous cell carcinoma and non-small cell lung cancer. SI-B001 (izalontamab) is a tetravalent bispecific monoclonal antibody targeting EGFR and HER3, designed to block signaling from both receptors and mediate immune cell effector functions against cancer cells[4]. SI-B003 (danvilostomig) is a tetravalent bispecific antibody targeting PD-1 and CTLA-4, aiming to restore anti-tumor activity of exhausted tumor-specific T cells through immune checkpoint inhibition[4]. Chemotherapy is administered concomitantly (typically platinum-based regimens[1][6]). The combination seeks to directly inhibit growth factor receptor-driven proliferation while enhancing anti-tumor immunity.
- Other names
- SI-B001 + SI-B003 + chemotherapy
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)ERBB3 (Erb-b2 receptor tyrosine kinase 3)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNATUBB (Tubulin (alpha and beta subunits))EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on SI-B001 + SI-B003 + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SI-B001 + SI-B003 + chemotherapy.